JP2019529520A - 胆道がんを処置する方法 - Google Patents

胆道がんを処置する方法 Download PDF

Info

Publication number
JP2019529520A
JP2019529520A JP2019518506A JP2019518506A JP2019529520A JP 2019529520 A JP2019529520 A JP 2019529520A JP 2019518506 A JP2019518506 A JP 2019518506A JP 2019518506 A JP2019518506 A JP 2019518506A JP 2019529520 A JP2019529520 A JP 2019529520A
Authority
JP
Japan
Prior art keywords
albumin
nanoparticles
composition
taxane
biliary tract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019518506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529520A5 (enExample
Inventor
マルクス レンシュラー，
マルクス レンシュラー，
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー, アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2019529520A publication Critical patent/JP2019529520A/ja
Publication of JP2019529520A5 publication Critical patent/JP2019529520A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019518506A 2016-10-07 2017-10-06 胆道がんを処置する方法 Pending JP2019529520A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405706P 2016-10-07 2016-10-07
US62/405,706 2016-10-07
PCT/US2017/055559 WO2018067943A1 (en) 2016-10-07 2017-10-06 Methods of treating biliary tract cancer

Publications (2)

Publication Number Publication Date
JP2019529520A true JP2019529520A (ja) 2019-10-17
JP2019529520A5 JP2019529520A5 (enExample) 2020-11-12

Family

ID=61831977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019518506A Pending JP2019529520A (ja) 2016-10-07 2017-10-06 胆道がんを処置する方法

Country Status (9)

Country Link
US (1) US20200129469A1 (enExample)
EP (1) EP3522887A4 (enExample)
JP (1) JP2019529520A (enExample)
KR (1) KR20190066033A (enExample)
AU (1) AU2017340913A1 (enExample)
BR (1) BR112019006329A2 (enExample)
CA (1) CA3039582A1 (enExample)
MX (1) MX2019003694A (enExample)
WO (1) WO2018067943A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EA036790B1 (ru) 2015-06-29 2020-12-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способ лечения злокачественной пекомы
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
WO2022140261A1 (en) * 2020-12-22 2022-06-30 Ambys Medicines, Inc. Biliary delivery methods, compositions and kits for use therein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523656A (ja) * 2010-03-26 2013-06-17 アブラクシス バイオサイエンス， エルエルシー 肝細胞がんの処置方法
JP2013533232A (ja) * 2010-06-07 2013-08-22 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
JP2014513138A (ja) * 2011-05-04 2014-05-29 インテリカイン， エルエルシー 併用の医薬組成物およびその使用
JP2016506908A (ja) * 2013-01-11 2016-03-07 アブラクシス バイオサイエンス， エルエルシー Ｋ−ｒａｓの変異状態に基づくがんの処置方法
US20160101128A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199404A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523656A (ja) * 2010-03-26 2013-06-17 アブラクシス バイオサイエンス， エルエルシー 肝細胞がんの処置方法
JP2013533232A (ja) * 2010-06-07 2013-08-22 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
JP2014513138A (ja) * 2011-05-04 2014-05-29 インテリカイン， エルエルシー 併用の医薬組成物およびその使用
JP2016506908A (ja) * 2013-01-11 2016-03-07 アブラクシス バイオサイエンス， エルエルシー Ｋ−ｒａｓの変異状態に基づくがんの処置方法
US20160101128A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol. 14, JPN6021028792, 2010, pages 363 - 367, ISSN: 0004716164 *
JOURNAL OF CANCER THERAPY, vol. 5, no. 6, JPN6021028793, 2014, pages 605 - 610, ISSN: 0004716163 *
PLOS ONE, JPN6021028794, 2015, pages 1 - 19, ISSN: 0004716162 *

Also Published As

Publication number Publication date
EP3522887A1 (en) 2019-08-14
MX2019003694A (es) 2019-06-24
CA3039582A1 (en) 2018-04-12
BR112019006329A2 (pt) 2019-06-25
EP3522887A4 (en) 2020-06-10
US20200129469A1 (en) 2020-04-30
AU2017340913A1 (en) 2019-04-18
KR20190066033A (ko) 2019-06-12
WO2018067943A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP6257324B2 (ja) 膵臓がんの処置方法
JP6697017B2 (ja) 膵臓がんの処置方法
TWI495467B (zh) 肝細胞癌之治療方法
JP2013527232A (ja) 膀胱がんの処置方法
JP6387389B2 (ja) 小児充実性腫瘍の処置の方法
JP2019529520A (ja) 胆道がんを処置する方法
JP2016513075A (ja) ヌクレオシド輸送体のレベルに基づくがんの処置方法
JP2016506908A (ja) Ｋ−ｒａｓの変異状態に基づくがんの処置方法
HK40009403A (en) Methods of treating pancreatic cancer
HK1239542A1 (zh) 治疗胰腺癌的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201005

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210406

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220301